Verastem Inc (VSTM) Stock Price, Quote & News

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 292 4200

Website: www.verastem.com

Address:

117 Kendrick Street, Suite 500, Needham, United States

MoneyGroupLLC Dec. 25 at 4:47 PM

Enter: $VSTM Calls Strike Price: $8 Expiry Date: JAN 16 2026 Buy in Price: $1.40 - $1.45 Sell Price: $2.68 Profit : +85% (Turn every $1 into $1.85) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

1iquid Dec. 25 at 4:24 AM

💎 Liquid® Live Actionable Trade Asset: $VSTM Contracts: $VSTM January 15, 2027 $10 Calls Scale in: $2.09- $2.56 Scale out: $8.14-$13.95 Profit Potential : 223% ROI Blended Join 💎 Here: https://1iquid.com

0 · Reply

SagehenNed Dec. 24 at 10:16 PM

$VSTM FYI Short interest as of: 11/14. 19.1 million 11/28. 18.4 12/15. 16.7 Looks like the shorts are covering a bit as the stock declines.

0 · Reply

Mattyk7 Dec. 24 at 5:44 PM

$VSTM see you all in 2026, the big buyers and institutions are on Holiday break. Drama will start back up Jan 5. This all is Nothing Sandwich, go enjoy your family.

0 · Reply

Robertbuote Dec. 24 at 5:03 PM

$VSTM 203 is dead. Amgen is not buying VSTM. There is no buy-out pending. If there were they never would have terminated the COO and replaced him with Chairman of the Board. You don’t play musical chairs wihh the Board and senior execs if you have a buy-out in the works.

1 · Reply

Teddy313 Dec. 24 at 4:36 PM

$VSTM Everything will change for the better after the first of the year. After listening to the chats I'm sure great news will be coming out. Everyone was so up beat I'm sure everyone will be happy. IMO. This year is finished as far as I'm concerned. On to 26 with all the great results. By the way there is still tax loss selling, not everyone has a profit.

0 · Reply

Marketismanipulated2 Dec. 24 at 3:26 PM

$VSTM fucking criminals! Nothing has changed when it was worth $10.50 3 weeks ago, NOTHING! This is the result of what SHOULD be illegal shorting. What a disgusting practice!🤬🤬🤬

0 · Reply

SagehenNed Dec. 24 at 3:24 PM

$VSTM XBI hitting new highs and we're in the red and remain stuck under 8. Guess we're going to have to wait until next year for any news/upward movement.

0 · Reply

PencilNeckGeek Dec. 24 at 3:12 PM

$VSTM Sucks that this can't even hold 8 bucks anymore

1 · Reply

PnLGlowLiteCore_1303 Dec. 24 at 2:33 PM

$VSTM biotech drifting sideways low attention squeeze risk on news or volume

0 · Reply

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

Nov 25, 2025, 7:30 AM EST - 4 weeks ago

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Nov 14, 2025, 12:41 AM EST - 5 weeks ago

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 13, 2025, 4:07 PM EST - 5 weeks ago

Verastem Oncology Announces Proposed Public Offering of Common Stock

Nov 5, 2025, 7:30 AM EST - 7 weeks ago

Verastem Oncology to Present at Upcoming Investor Conferences

Nov 4, 2025, 10:16 AM EST - 7 weeks ago

Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:30 AM EST - 7 weeks ago

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Oct 23, 2025, 4:01 PM EDT - 2 months ago

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Oct 23, 2025, 7:30 AM EDT - 2 months ago

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 19, 2025, 4:15 AM EDT - 2 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Oct 7, 2025, 7:30 AM EDT - 2 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2025, 4:29 PM EDT - 4 months ago

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Aug 8, 2025, 8:55 PM EDT - 4 months ago

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Jul 29, 2025, 7:30 AM EDT - 5 months ago

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 7:30 AM EDT - 5 months ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Jul 16, 2025, 8:22 AM EDT - 5 months ago

Verastem: The Market Is Ignoring The Progress

Jul 11, 2025, 4:12 PM EDT - 5 months ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Jun 30, 2025, 4:02 PM EDT - 6 months ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 26, 2025, 11:16 AM EDT - 6 months ago

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Jun 24, 2025, 4:02 PM EDT - 6 months ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 2, 2025, 9:40 AM EDT - 7 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

May 28, 2025, 7:30 AM EDT - 7 months ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 5:01 PM EDT - 7 months ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 20, 2025, 8:30 AM EDT - 7 months ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

May 13, 2025, 4:34 PM EDT - 8 months ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 8, 2025, 1:17 PM EDT - 8 months ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 12:23 PM EDT - 8 months ago

U.S. FDA approves Verastem's cancer therapy

Apr 25, 2025, 9:00 AM EDT - 8 months ago

Verastem Oncology Announces $75 million Private Placement

Apr 23, 2025, 4:05 PM EDT - 8 months ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 10, 2025, 2:35 PM EDT - 9 months ago

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Mar 25, 2025, 4:35 PM EDT - 9 months ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 20, 2025, 4:01 PM EDT - 9 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Feb 20, 2025, 4:05 PM EST - 10 months ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Jan 29, 2025, 7:30 AM EST - 11 months ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 15, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 14, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 13, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Jan 3, 2025, 11:56 AM EST - 1 year ago

Verastem: Planning The PDUFA Run-Up

Jan 2, 2025, 11:39 AM EST - 1 year ago

Verastem: BLA Acceptance Puts Key Goals In Sight

Dec 31, 2024, 10:59 AM EST - 1 year ago

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Dec 30, 2024, 4:30 PM EST - 1 year ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Dec 18, 2024, 7:30 AM EST - 1 year ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Nov 27, 2024, 1:28 PM EST - 1 year ago

Verastem: Preparing For Upcoming Catalysts

Nov 26, 2024, 7:00 AM EST - 1 year ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 6, 2024, 4:05 PM EST - 1 year ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology to Participate in Upcoming Investor Conferences

Oct 17, 2024, 1:00 AM EDT - 1 year ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

MoneyGroupLLC Dec. 25 at 4:47 PM

0 · Reply

1iquid Dec. 25 at 4:24 AM

0 · Reply

SagehenNed Dec. 24 at 10:16 PM

$VSTM FYI Short interest as of: 11/14. 19.1 million 11/28. 18.4 12/15. 16.7 Looks like the shorts are covering a bit as the stock declines.

0 · Reply

Mattyk7 Dec. 24 at 5:44 PM

$VSTM see you all in 2026, the big buyers and institutions are on Holiday break. Drama will start back up Jan 5. This all is Nothing Sandwich, go enjoy your family.

0 · Reply

Robertbuote Dec. 24 at 5:03 PM

1 · Reply

Teddy313 Dec. 24 at 4:36 PM

0 · Reply

Marketismanipulated2 Dec. 24 at 3:26 PM

$VSTM fucking criminals! Nothing has changed when it was worth $10.50 3 weeks ago, NOTHING! This is the result of what SHOULD be illegal shorting. What a disgusting practice!🤬🤬🤬

0 · Reply

SagehenNed Dec. 24 at 3:24 PM

$VSTM XBI hitting new highs and we're in the red and remain stuck under 8. Guess we're going to have to wait until next year for any news/upward movement.

0 · Reply

PencilNeckGeek Dec. 24 at 3:12 PM

$VSTM Sucks that this can't even hold 8 bucks anymore

1 · Reply

PnLGlowLiteCore_1303 Dec. 24 at 2:33 PM

$VSTM biotech drifting sideways low attention squeeze risk on news or volume

0 · Reply

Drew613 Dec. 24 at 1:40 PM

$VSTM IMO, Amgen will acquire VSTM. They have not made any acquisitions this past year and sit on over $12B. Just a hunch. Merry Christmas to all!

2 · Reply

SagehenNed Dec. 24 at 1:24 PM

$VSTM Lots of volume pre-market this morning - over 64,000. Any news out there??

2 · Reply

Timboslice88 Dec. 24 at 1:10 PM

$VSTM sold at 10.50 to move over to $SLS Got back in pre market today at 7.90. Great value at this price

0 · Reply

Marketismanipulated2 Dec. 24 at 10:44 AM

$VSTM so in an an organic market this should now soar but shorts will harp on any little negative even if 99% was great to try to tank it. Better fly!

0 · Reply

Marketismanipulated2 Dec. 24 at 10:32 AM

$VSTM so apparently Ramp 203 was good according to what I'm reading with no dosing toxicities. 2 of 3 patients had 20% tumor reduction after prior exhausted therapies. Now this SHOULD be great news with the stock running up but in today's upside down manipulated market, don't be surprised if they find one excuse to tank it.

2 · Reply

TradeWoFear Dec. 24 at 7:51 AM

$VSTM Very interesting !! Forecasted by CNN!!! i will leave the guess to you!!!

1 · Reply

DianeByard363 Dec. 24 at 7:39 AM

$VSTM Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

0 · Reply

Ralphjayala Dec. 24 at 6:59 AM

$VSTM

1 · Reply

MoneyGroupLLC Dec. 24 at 6:54 AM

Enter: $VSTM Calls Strike Price: $8 Expiry Date: JAN 16 2026 Buy in Price: $1.40 - $1.47 Sell Price: $2.41 Profit : +72% (Turn every $1 into $1.72) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

jacksparo Dec. 23 at 9:50 PM

$SLS $OCGN $LAES $VSTM Market closed for the regular trading hours. Time to get another few oz of coffee and research the volume status for the regular hours!

1 · Reply

sweddle Dec. 23 at 9:47 PM

$VSTM wonder about the remaining warrants ? Warrant holders have to make a decision by end of January

1 · Reply

Stoltz13 Dec. 23 at 8:47 PM

$VSTM slowly but surely chugging up the hill again...

0 · Reply

Market Cap	529.53M
Revenue (ttm)	10.00M
Net Income (ttm)	-130.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,306.40%
Debt to Equity Ratio	-5.03

Volume	734,700
Avg Vol	2,407,824
Day's Range	N/A - N/A
Shares Out	66.78M
Stochastic %K	12%
Beta	0.41
Analysts	Strong Sell
Price Target	$16.00